CT-Luso is an Ethical and Regulatory Training Project for carrying out Clinical Trials in Portuguese-speaking African Countries, proposed by the Portuguese Pharmaceutical Society, approved and financed by the EDCTP3 Program, a Partnership between Europe and Countries in Development for the Conduct of Clinical Trials, and with the support of the European Commission.
This is an aggregating project that involves Angola, Cabo Verde, Guinea Bissau, Mozambique, Sao Tome and Principe and Portugal, through the Ethics Authorities and Regulatory Authorities, National Institutes of Health, Universities, among other institutions, from each of the partner countries, in a total of 24 entities, bringing together experts in ethics, regulation, biomedical research and clinical trials.
The launch session of the CT-Luso project takes place on April 4th, in Maputo, with online transmission to all the partner countries. The event marks the official beginning of the project and it is an opportunity to align objectives and expectations, draw up action plans, and reiterate commitments and scheduled goals.
CT-Luso was built on the solid foundations or excellent results obtained by BERC-Luso, the Ethical and Regulatory Training Project in Portuguese-speaking African Countries, approved and financed by the EDCTP2 Program, which took place between 2018 and 2022.
In all partner countries, Berc-Luso achieved a high level of success by meeting the initial objectives. A total of 311 activities were conducted, benefiting at least 3848 professionals from diverse fields. Over 172 hours of training were delivered and the project gained extensive publicity through television, radio and other media outlets across at least six countries.
The objective of CT-Luso now is to expand it, expanding it to more partner institutions and a greater number of trainees, and focusing on the implementation of clinical trials, deepening the process from theory to effective practice and intensifying specialization. This new path should lead to creation of a harmonized Portuguese-speaking nucleus capable of international clinical trials.
